What This Bill Does · Plain English
GovGreed Synthesis · AI extraction
This bill amends the Social Security Act to extend the period of protection from Medicare price negotiation for certain drugs. Specifically, it changes the definition of a 'qualifying single source drug' to give drugs that use 'genetically targeted technologies' an 11-year exemption from price negotiation, instead of the standard 7-year period. This would apply to drugs that modulate gene function, such as some gene therapies and other advanced biologics.
Frequently Asked Questions
Did HR.5547 pass?
HR.5547 did not pass and is no longer active. Final stage: COMMITTEE.
What does HR.5547 do?
This bill amends the Social Security Act to extend the period of protection from Medicare price negotiation for certain drugs. Specifically, it changes the definition of a 'qualifying single source drug' to give drugs that use 'genetically targeted technologies' an 11-year exemption from price negotiation, instead of the standard 7-year period. This would apply to drugs that modulate gene function, such as some gene therapies and other advanced biologics.
Full Bill Text
118 HR 5547 IH: Maintaining Investments in New Innovation Act U.S. House of Representatives 2023-09-18 text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. I 118th CONGRESS 1st Session H. R. 5547 IN THE HOUSE OF REPRESENTATIVES September 18, 2023 Mr. Nickel (for himself, Mr. Joyce of Pennsylvania , and Mr. Davis of North Carolina ) introduced the following bill; which was referred to the Committee on Energy and Commerce , and in addition to the Committee on Ways and Means , for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned A BILL To amend title XI of the Social Security Act to protect access to genetically targeted technologies. 1. Short title This Act may be cited as the Maintaining Investments in New Innovation Act . 2. Amendment to definition of qualifying single source drug Section 1192(e) of the Social Security Act ( 42 U.S.C. 1320f–1(e) ) is amended— (1) in paragraph (1)(A)(ii), by inserting (or, in the case of an advanced drug product (as defined in paragraph (4)), 11 years) after 7 years ; and (2) by adding at the end the following new paragraph: (4) Advanced drug product defined For purposes of paragraph (1)(A)(ii), the term advanced drug product means a drug that incorporates or utilizes a genetically targeted technology (as defined in section 529A(c)(2) of the Federal Food, Drug, and Cosmetic Act) that may result in the modulation (including suppression, up-regulation, or activation) of the function of a gene or its associated gene product. .
Loading intelligence layer…